Hyloris Pharmaceuticals SA (DE:52U)
FRANKFURT:52U
Holding DE:52U?
Track your performance easily

Hyloris Pharmaceuticals SA (52U) Income Statement

1 Followers

Hyloris Pharmaceuticals SA Income Statement

Last quarter (Q2 2022), Hyloris Pharmaceuticals SA's total revenue was €―, a decrease of -100.00% from the same quarter last year. In Q2, Hyloris Pharmaceuticals SA's net income was €―. See Hyloris Pharmaceuticals SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
€ 19.00K€ 3.10M€ 175.00K€ 91.00K€ 91.00K€ 213.00K
Cost of Revenue
€ 89.00K€ 107.00K€ 145.00K€ 66.00K€ 65.00K€ 95.00K
Gross Profit
€ -70.00K€ 2.99M€ 30.00K€ 25.00K€ 26.00K€ 118.00K
Operating Expense
€ 2.30M€ 13.34M€ 5.61M€ 5.30M€ 5.50M€ 3.98M
Operating Income
€ -2.37M€ -10.35M€ -5.58M€ -5.27M€ -5.47M€ -3.87M
Net Non Operating Interest Income Expense
€ 51.00K€ -550.00K€ -478.00K€ -508.00K€ -345.00K€ -148.00K
Other Income Expense
------
Pretax Income
€ -2.16M€ -11.28M€ -7.14M€ -5.78M€ -6.06M€ -3.78M
Tax Provision
-€ 297.00K€ 1.00K€ -14.00K€ -20.00K€ -66.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -2.16M€ -11.58M€ -7.14M€ -5.37M€ -5.79M€ -3.72M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 2.39M€ 13.44M€ 5.75M€ 5.37M€ 5.56M€ 4.08M
Net Income From Continuing And Discontinued Operation
€ -2.16M€ -11.58M€ -7.14M€ -5.37M€ -5.79M€ -3.72M
Normalized Income
€ -2.16M€ -11.58M€ -7.20M€ -5.37M€ -5.79M€ -3.72M
Interest Expense
€ 476.00K€ 556.00K€ 992.00K€ 518.00K€ 340.00K€ 146.00K
EBIT
€ -1.69M€ -10.73M€ -6.15M€ -5.26M€ -5.72M€ -3.64M
EBITDA
€ -1.66M€ -10.59M€ -5.57M€ -1.96M€ -5.63M€ -3.57M
Currency in EUR

Hyloris Pharmaceuticals SA Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis